An observational study in Plasma Cell Disorder, sponsored by Siriraj Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-26.
Sponsored by Siriraj Hospital · Observational
The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand. The main questions it aims to answer are:
The FISH and/or NGS testing results, disease characteristics, treatment, and treatment outcomes of patients with plasma cell disorders who underwent FISH and/or NGS testing before IRB approval will be collected through retrospective chart review. Subsequently, data will be gathered prospectively. Participants will provide approximately 12 mL of bone marrow fluid for FISH and NGS testing.
86 studies on the registry are indexed under Paraproteinemias; 28 are open to participants now.
This study's planned enrollment of 498 is above the median of 300 across 35 observational studies indexed under Paraproteinemias.
Browse Paraproteinemias studies →Siriraj Hospital is the lead sponsor of 95 studies on the registry; 32 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis who were performed FISH and/or NGS testing
Exclusion Criteria:
genetic landscape of PCD
number and percentage of genetic landscape of FISH and NGS in patients with Plasma Cell Disorders
Time frame: 18 months in 498 patients
genetic correlation
genetic landscape correlation between FISH and NGS in MM patients
Time frame: 18 months in MM patients
genetic landscape of relapse MM patients
number of genetic landscape in relapse MM patients
Time frame: 18 months in MM patients
overall survival
time of survival in MM patients
Time frame: 18 months
progression free survival
time of disease progression in MM patients
Time frame: 18 months
factor of genetic landscape differentiation
number of MM patients who have the different factors such as gender, age, and comorbidities.
Time frame: 18 months in MM patients
gender
number and percentage of male and female
Time frame: 18 months in 498 patients
age
age in years
Time frame: 18 months in 498 patients
No study locations are listed for this record.
Plan to share: Undecided — Need a consensus from colleagues
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Siriraj Hospital